Clinical trial
Single-centre, Randomised, Placebo-controlled, Double-blind, Dose Escalation Trial Investigating Pharmacokinetics, Pharmacodynamics and Tolerability of Three Different Single Intravenous Doses of Activated Recombinant Factor VIIa (rFVIIa/NovoSeven®) in Healthy Caucasian and Japanese Subjects
NCT01563471 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-centre, Randomised, Placebo-controlled, Double-blind, Dose Escalation Trial Investigating Pharmacokinetics, Pharmacodynamics and Tolerability of Three Different Single Intravenous Doses of Activated Recombinant Factor VIIa (rFVIIa/NovoSeven®) in Healthy Caucasian and Japanese Subjects
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2001
- Completion date
- July 31, 2002
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors, healthy